SAN DIEGO--(BUSINESS WIRE)--OrexigenTM Therapeutics, Inc. (NASDAQ: OREX) today announced the public offering of 7,000,000 shares of common stock at a price of $11.00 per share. All shares are being offered by Orexigen. In addition, Orexigen has granted the underwriters a 30-day option to purchase an additional 1,050,000 shares to cover overallotments, if any. Merrill Lynch & Co. acted as sole book-running manager and Leerink Swann LLC acted as co-lead manager for the offering. JMP Securities LLC, Lazard Capital Markets, Canaccord Adams Inc. and Natixis Bleichroeder Inc. acted as co-managers for the offering. A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on January 23, 2008. Any offer or sale will be made only by means of a written prospectus forming part of the effective registration statement. Copies of the final prospectus relating to the offering may be obtained from: Merrill Lynch & Co., 4 World Financial Center, New York, NY 10080.
